0 0.00

Shopping Cart ( 0 )

Your Have 0 Item In Your Cart

close

No products in the cart.

Drug Target Pathways

  • Home
  • Drug Target Pathways

Vedicinals® 9 : The Composition for management of COVID-19 & Preventing LONG COVID

At the early stage of the COVID-19 pandemic Vedicinals’s research teams started detailed meta-analysis of past studies of various therapeutic molecules, computational docking studies and also developed a scientific rationale that would ensure the best possible outcomes leading to a COVID-19 therapeutic formulation.

The observation that COVID-19 is a multi -systemic condition with various degrees of disease severity and affects various body regions, with little influence on which state of disease progression therapeutic intervention was initiated added intense complexity to the tasks of developing a truly effective therapeutic.

However, we circumvented all obstacles by developing a strategy that focused on addressing the various identified desired drug target pathways.

This identified list of confirmed and possible drug target pathways was then used as a multiple selection criteria for the most potent molecules, in most cases each molecule covering multiple target pathways.

The initially identified 612 plus molecule candidates were then submitted to an advanced selection process that would take several additional criteria into consideration, like: past experience and data on potency, side effects, drug interactions bioavailability, synergies between the combined compounds,
large scale availability of raw materials in the region and many other important criteria.

Most of our extensive research work was based on available global meta-analysis of existing in vivo human and animal studies, as well as cell culture studies and access to critical published data.

This formed the basis for further preclinical, toxicity, and human clinical trial evaluations that confirmed all previous research with excellent treatment outcomes.

The Composition for management of COVID-19 & Preventing LONG COVID

##
Drug Target pathways
Active Ingredients
STRUCTURAL PROTEINS OF SARS_CoV_2
1
2
3
4
5
6
7
8
9
1 3C-LIKE PROTEASE (3CL. 6LU7_INHIBITORS)
2 SPIKE GLYCOPROTEIN 6LYEST INHIBITORS
3 ENVELOPE GYLCOPROTIEN INHIBITORS
4 NUCLEOCAPSID PROTEIN INHIBITORS
5 PAPAIN-LIKE PROTEASE (PL. INHIBITORS)
6 RNA-DEPENDANT RNA POLYMERASE (Rd INHIBITORS)
7 HELICASE INHIBITORS
8 RBD-ACE 2 6VW11 INHIBITORS
HOST RECEPTORS / CELLS / ENZYMES
1
2
3
4
5
6
7
8
9
9 ZINC IONOPHORES
10 DHODH INHIBITORS
11 ENDOCYTOSIS INHIBITORS
12 HEME OXYGENASE (HO-1) ACTIVATORS
13 TMPRSS2 INHIBITORS
14 FURIN INHIBITORS
15 TRYPSIN INHIBITORS
16 CATHEPSIN-L INHIBITORS
17 APN & CD 13 INHIBITORS
18 DPP4 INHIBITORS
19 CALPAIN INHIBITORS
20 CASEIN KINASE-2 (CK2) INHIBITORS
21 EMMPRIN CD 147 INHIBITORS
22 GRP 78 INHIBITORS
23 GP 41 FUSION INHIBITORS
24 ANGIOTENSIN II INHIBITORS
25 PALS 1 INHIBITORS
26 P-SELECTIN INHIBITORS
27 HEPARAN SULFATE BINDING INHIBITORS
28 CCR5 INHIBITORS
29 MYOSIN II & FILOPODIA ADHESION INHIBITORS
30 TYROSINE KINASE INHIBITORS
31 PPAR GAMMA ACTIVATORS
32 SYNCYTIUM / SYNCYTIA FORMATION INHIBITORS
MANAGEMENT OF COVID 19 & PREVENTION OF LONG COVID
1
2
3
4
5
6
7
8
9
33 INTERLEUKIN – 6 INHIBITORS
34 MACROPHAGE POLARISATION & CCL2 REGULATORS
35 PRO-INFLAMMATORY CYTOKINE SuPPRESSORS
36 TNF ALPHA SUPPRESSORS
37 MAST CELLS STABILIZERS
38 T CELLS STABILIZERS
39 Nrf2_ ACTIVATORS
40 NLRP-3 & CASPASE-1 INHIBITORS
41 STAT 3 PHOSPHORYLATION SUPPRESSORS
42 ALPHA ANTI TRYPSIN ACTIVATORS
43 C REACTIVE PROTEIN SUPPRESSORS
44 CREATININE KINEASE INHIBITORS
45 RAISING ANTIBODY LEVELS
46 PROTECTING LUNG TISSUES
47 PROTECTING NEURONAL TISSUES
48 PROTECTING KIDNEY TISSUES
49 PROTECTING CARDIO-VASCULAR SYSTEM
50 PROTECTING MYOCARDIAL TISSUES
51 BDNF & REMYELINATION AGONISTS
52 PROTECTING AGAINST THROMBOSIS
53 PROTECTING PANCREATIC BETA CELLS
54 PROTECTING LIVER TISSUES
55 TREATMENT OF BACTERIAL CO-INFECTION
56 MODULATING GUT BACTERIA & GUT BRAIN AXIS
57 TREATMENT OF INTESTINAL INFLAMMATION
58 TREATMENT OF ENCEPHALOMYELITIS
59 MANAGING HYPERGLYCEMIA
60 PROTECTING AGAINST MITOCHONDRIAL DAMAGE
61 PROTECTING & RESTORING TIGHT JUNCTIONS {INTESTINAL & BBB}
62 SENOLYTICS
PROTECTING & TREATMENT OF AUTO-IMMUNE CONDITIONS
1
2
3
4
5
6
7
8
9
63 TREATMENT OF CO-INFECTIONS
64 TREATMENT OF MALARIA CO-INFECTION
65 TREATMENT OF TUBERCULOSIS CO-INFECTION
66 TREATMENT OF DENGUE CO-INFECTION
67 TREATMENT OF INFLUENZA CO-INFECTION
70 RETROVIRUS & REVERSE TRANSCRIPTASE INHIBITORS
71 TREATMENT OF HIV CO-INFECTION

Please Note: Confidential !! Patent Pending Information of VEDICINALS INDIA PVT LTD.

Translate